Product Information
PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $3.0564 per EA under NDC 00480329656. Its NADAC has been published 59 times since Aug 20, 2025.
FDA first approved this application on Jun 25, 2024. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
7.5; 46 mg/1; mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00480329656
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PHENTERMINE HYDROCHLORIDE; TOPIRAMATEApproval Type
Generic (ANDA)
FDA Application
ANDA204982FDA Approved
6/25/2024
TE Code
AB
On Market Since
5/7/2025
Pharmacological Classes
Price Statistics
The NADAC for PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE has been published 59 times since Aug 20, 2025, and over the history we have for it it has declined 34.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.0564 per EA |
|---|---|
| All-time high | $4.6508 (Sep 10, 2025) |
| All-time low | $3.0564 (Sep 23, 2026) |
| 52-week high | $3.9883 |
| 52-week low | $3.0564 |
| Median price | $3.3727 |
| Average price | $3.5421 |
| Largest weekly change | -14.2% (Sep 17, 2025) |
| Weeks tracked | 59 |
| Tracking since | Aug 20, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Phentermine and topiramate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Phentermine and topiramate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Sympathomimetic Amine Anorectic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE, manufactured by Teva Pharmaceuticals USA Inc., is $3.0564 per EA (NDC 00480329656), effective Sep 30, 2026.
How has the price of PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE has declined 34.3%. It has been tracked across 59 weekly CMS publications since Aug 20, 2025.
What are the highest and lowest recorded NADAC prices for PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE?
Since Aug 20, 2025, the NADAC for PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE has ranged from a low of $3.0564 (Sep 23, 2026) to a high of $4.6508 (Sep 10, 2025), with a median of $3.3727 per EA.
Are there cheaper alternatives to PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE?
PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE (NDC 00480329656) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.